Rigel Pharmaceuticals Files 8-K Update
Ticker: RIGL · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1034842
| Field | Detail |
|---|---|
| Company | Rigel Pharmaceuticals Inc (RIGL) |
| Form Type | 8-K |
| Filed Date | Jan 13, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financial-update, operations
TL;DR
Rigel Pharma dropped an 8-K on Jan 13th - check financials and operations.
AI Summary
Rigel Pharmaceuticals, Inc. filed an 8-K on January 13, 2025, reporting on its results of operations, financial condition, and other events. The filing also includes financial statements and exhibits, providing an update on the company's status.
Why It Matters
This 8-K filing provides crucial updates on Rigel Pharmaceuticals' financial performance and operational events, which can impact investor decisions.
Risk Assessment
Risk Level: low — This is a routine filing providing operational and financial updates, not indicating immediate significant risk.
Key Players & Entities
- Rigel Pharmaceuticals, Inc. (company) — Registrant
- January 13, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 611 Gateway Boulevard Suite 900 (address) — Principal executive offices
- South San Francisco, CA (location) — City, State of principal executive offices
- 94080 (zip_code) — Zip code of principal executive offices
- (650) 624-1100 (phone_number) — Registrant's telephone number
FAQ
What specific financial results are being reported in this 8-K?
The filing indicates it covers 'Results of Operations and Financial Condition' but does not provide specific figures within the provided text.
What 'Other Events' are being reported by Rigel Pharmaceuticals?
The filing lists 'Other Events' as an item of information but does not detail what those events are in the provided text.
When was this 8-K filing submitted?
The filing was submitted on January 13, 2025.
Where is Rigel Pharmaceuticals, Inc. headquartered?
Rigel Pharmaceuticals, Inc. is headquartered at 611 Gateway Boulevard, Suite 900, South San Francisco, CA 94080.
What is the primary business of Rigel Pharmaceuticals, Inc. according to the filing?
The Standard Industrial Classification code indicates the company is in 'PHARMACEUTICAL PREPARATIONS [2834]'.
Filing Stats: 525 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2025-01-13 08:15:12
Key Financial Figures
- $0.001 — h Registered Common Stock, par value $0.001 per share RIGL The Nasdaq Stock Mar
Filing Documents
- tm253048d1_8k.htm (8-K) — 24KB
- tm253048d1_ex99-1.htm (EX-99.1) — 54KB
- 0001104659-25-002874.txt ( ) — 259KB
- rigl-20250113.xsd (EX-101.SCH) — 3KB
- rigl-20250113_lab.xml (EX-101.LAB) — 33KB
- rigl-20250113_pre.xml (EX-101.PRE) — 22KB
- tm253048d1_8k_htm.xml (XML) — 4KB
02. Results of Operations and Financial Conditions
Item 2.02. Results of Operations and Financial Conditions. In connection with the press release described in Item 8.01 below, on January 13, 2025, Rigel Pharmaceuticals, Inc. ("Rigel") provided, on a preliminary and unaudited basis, certain estimated financial results for its fourth quarter and fiscal year ended December 31, 2024. The preliminary estimates are based on currently available information and do not present all necessary information for a complete understanding of Rigel's financial condition as of December 31, 2024 or Rigel's results of operations for the fourth quarter or fiscal year ended December 31, 2024.
01. Other Events
Item 8.01. Other Events. On January 13, 2025, Rigel issued a press release titled "Rigel Provides Business Update and 2025 Outlook." A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Description 99.1 Press Release, dated January 13, 2025, titled "Rigel Provides Business Update and 2025 Outlook." 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 13, 2025 RIGEL PHARMACEUTICALS, INC. By: /s/ Raymond J. Furey Raymond J. Furey Executive Vice President, General Counsel, Chief Compliance Officer, and Corporate Secretary